Literature DB >> 32574773

Macular and Peripapillary Optical Coherence Tomography Angiography Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data.

Eugenia Custo Greig1, Mitchell Brigell2, Frank Cao3, Emily S Levine4, Kevin Peters2, Eric M Moult5, James G Fujimoto5, Nadia K Waheed6.   

Abstract

PURPOSE: To identify optical coherence tomography angiography (OCTA)-derived vessel metrics of the macula and optic nerve head (ONH) that predict diabetic retinopathy (DR) disease progression.
DESIGN: Secondary analysis of clinical trial data.
METHODS: This was a sub-analysis of prospectively collected data from 73 subjects that participated in the TIME-2b study (Aerpio Pharmaceuticals), a multicenter clinical trial for patients with moderate-to-severe DR treated with AKB-9778 and followed over a 12-month period. Eligible subjects were tested every 3 months with color fundus photography, spectral-domain OCT, and slit-lamp biomicroscopy. OCTA of the macula and ONH was obtained for a subset of patients enrolled at participating sites. En face, full-depth retinal projections centered at the macula were analyzed for multiple metrics including foveal avascular zone (FAZ) area and perimeter, nonperfusion area, vessel density (VD), and presence of intraretinal microvascular abnormalities (IRMA). VD of the radial peripapillary capillaries was evaluated in 4 quadrants surrounding the optic disc for ONH images. Progression was defined as a ≥2-step increase in DR severity scale score or development of diabetic macular edema.
RESULTS: Over a follow-up period of 12 months, 15 of 73 (20.5%) subjects progressed. At pretreatment baseline, larger FAZ area, presence of IRMA, and reduced peripapillary VD in the superior temporal and inferior temporal regions were significantly associated with increased odds of progression.
CONCLUSIONS: FAZ area and temporal peripapillary VD are predictors of DR progression. OCTA metrics may improve progression risk assessment in DR when compared to established risk factors alone.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2020        PMID: 32574773     DOI: 10.1016/j.ajo.2020.06.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Detection of the Microvascular Changes of Diabetic Retinopathy Progression Using Optical Coherence Tomography Angiography.

Authors:  Xiaogang Wang; Yongqing Han; Gang Sun; Fang Yang; Wen Liu; Jing Luo; Xing Cao; Pengyi Yin; Frank L Myers; Liang Zhou
Journal:  Transl Vis Sci Technol       Date:  2021-06-01       Impact factor: 3.283

Review 2.  Optical coherence tomography angiography in the management of diabetic retinopathy.

Authors:  Enrico Borrelli; Riccardo Sacconi; Giuseppe Querques; Francesco Bandello
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

3.  Application of Improved U-Net Convolutional Neural Network for Automatic Quantification of the Foveal Avascular Zone in Diabetic Macular Ischemia.

Authors:  Yongan Meng; Hailei Lan; Yuqian Hu; Zailiang Chen; Pingbo Ouyang; Jing Luo
Journal:  J Diabetes Res       Date:  2022-02-26       Impact factor: 4.011

4.  Quantitative Parameters from OCT Angiography in Patients with Diabetic Retinopathy and in Those with Only Peripheral Retinopathy Compared with Control Participants.

Authors:  Ruth E Hogg; David M Wright; Rosa Dolz-Marco; Calum Gray; Nadia Waheed; Michel M Teussink; Timos Naskas; Jennifer Perais; Radha Das; Nicola Quinn; George Bontzos; Constantinos Nicolaou; Kaushik Annam; Ian S Young; Frank Kee; Bernadette McGuiness; Gareth Mc Kay; Tom MacGillivray; Tunde Peto; Usha Chakravarthy
Journal:  Ophthalmol Sci       Date:  2021-05-26

5.  Optical Coherence Tomography Angiography Metrics Monitor Severity Progression of Diabetic Retinopathy-3-Year Longitudinal Study.

Authors:  Inês P Marques; Sophie Kubach; Torcato Santos; Luís Mendes; Maria H Madeira; Luis de Sisternes; Diana Tavares; Ana Rita Santos; Warren Lewis; Conceição Lobo; Mary K Durbin; José Cunha-Vaz
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.